JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 83 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $27,000 | +22.7% | 3,578 | +11.6% | 0.00% | 0.0% |
| Q2 2021 | $22,000 | -40.5% | 3,207 | -10.2% | 0.00% | -50.0% |
| Q1 2021 | $37,000 | +27.6% | 3,573 | +3.5% | 0.00% | 0.0% |
| Q3 2020 | $29,000 | +3.6% | 3,451 | -14.4% | 0.00% | 0.0% |
| Q2 2020 | $28,000 | +460.0% | 4,033 | +321.9% | 0.00% | – |
| Q1 2020 | $5,000 | -95.3% | 956 | -92.1% | 0.00% | -100.0% |
| Q4 2019 | $106,000 | +55.9% | 12,150 | -39.7% | 0.01% | +20.0% |
| Q3 2019 | $68,000 | +172.0% | 20,139 | +300.1% | 0.01% | +150.0% |
| Q2 2019 | $25,000 | +177.8% | 5,034 | +249.6% | 0.00% | +100.0% |
| Q1 2019 | $9,000 | 0.0% | 1,440 | -48.9% | 0.00% | 0.0% |
| Q4 2018 | $9,000 | -30.8% | 2,820 | +38.6% | 0.00% | 0.0% |
| Q3 2018 | $13,000 | -99.2% | 2,034 | +911.9% | 0.00% | – |
| Q2 2018 | $1,540,000 | +25566.7% | 201 | -23.6% | 0.00% | -100.0% |
| Q1 2018 | $6,000 | -25.0% | 263 | -46.3% | 0.00% | 0.0% |
| Q3 2017 | $8,000 | – | 490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |